Iteos Therapeutics Inc (ITOS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Iteos Therapeutics Inc (ITOS) has a cash flow conversion efficiency ratio of -0.086x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-42.45 Million) by net assets ($493.80 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See ITOS defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Iteos Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Iteos Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Iteos Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Iteos Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Chengdu Tianjian Technology Co Ltd
SHE:002977
|
-0.056x |
|
Hillstone Networks Co Ltd
SHG:688030
|
-0.042x |
|
Canada Goose Holdings Inc
TO:GOOS
|
0.181x |
|
Frp Holdings Ord
NASDAQ:FRPH
|
0.021x |
|
Wave Cyber Shanghai Co Ltd
SHG:688718
|
0.028x |
|
Energy Recovery Inc
NASDAQ:ERII
|
0.114x |
|
Jiangsu Yuxing Film Tech
SHE:300305
|
-0.016x |
|
Nanjing Aolian Ae&Ea Co Ltd
SHE:300585
|
0.027x |
Annual Cash Flow Conversion Efficiency for Iteos Therapeutics Inc (2018–2024)
The table below shows the annual cash flow conversion efficiency of Iteos Therapeutics Inc from 2018 to 2024. For the full company profile with market capitalisation and key ratios, see ITOS company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $590.29 Million | $-98.18 Million | -0.166x | +7.79% |
| 2023-12-31 | $575.23 Million | $-103.76 Million | -0.180x | -7.60% |
| 2022-12-31 | $663.33 Million | $-111.19 Million | -0.168x | -118.06% |
| 2021-12-31 | $552.82 Million | $513.14 Million | 0.928x | +1291.61% |
| 2020-12-31 | $323.20 Million | $-25.18 Million | -0.078x | +94.73% |
| 2019-12-31 | $15.67 Million | $-23.14 Million | -1.477x | -16.43% |
| 2018-12-31 | $15.05 Million | $-19.10 Million | -1.269x | -- |
About Iteos Therapeutics Inc
iTeos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of T-cell immunoreceptor with Ig and ITIM domains (TIGIT), as well as engages the Fc gamma receptor to activate dendritic cells, natural killer cells, T lym… Read more